The Journal of Allergy and Clinical Immunology
Volume 116, Issue 2 , Pages 241-249 , August 2005

Innate immune responses to infection

  • Michael F. Tosi, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Michael F. Tosi, MD, Division of Pediatric Infectious Diseases, Maimonides Medical Center, 977 48th St, Brooklyn, NY 11219.

Received 17 May 2005 ,Accepted 18 May 2005.

References 

  1. Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197–216
  2. Padlan EA. Anatomy of the antibody molecule. Mol Immunol. 1994;31:169–217
  3. Garcia KC, Teyton L, Wilson IA. Structural basis of T cell recognition. Annu Rev Immunol. 1999;17:369–397
  4. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003;3:710–720
  5. Oppenheim JJ, Biragyn A, Kwak LW, Yang D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis. 2003;62(suppl 2):17–21
  6. Vora P, Youdim A, Thomas LS, Fukata M, Tesfay SY, Lukasek K, et al. Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol. 2004;173:5398–5405
  7. Hertz CJ, Wu Q, Porter EM, Zhang YJ, Weismuller KH, Godowski PJ, et al. Activation of Toll-like receptor 2 on human tracheobronchial epithelial cells induces the antimicrobial peptide human beta defensin-2. J Immunol. 2003;171:6820–6826
  8. Hoover DM, Rajashankar KR, Blumenthal R, Puri A, Oppenheim JJ, Chertov O, et al. The structure of human beta-defensin-2 shows evidence of higher order oligomerization. J Biol Chem. 2000;275:32911–32918
  9. Campos MA, Vargas MA, Regueiro V, Llompart CM, Alberti S, Bengoechea JA. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun. 2004;72:7107–7114
  10. Jin T, Bokarewa M, Foster T, Mitchell J, Higgins J, Tarkowski A. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J Immunol. 2004;172:1169–1176
  11. Perregaux DG, Bhavsar K, Contillo L, Shi J, Gabel CA. Antimicrobial peptides initiate IL-1 beta posttranslational processing: a novel role beyond innate immunity. J Immunol. 2002;168:3024–3032
  12. Hoover DM, Boulegue C, Yang D, Oppenheim JJ, Tucker K, Lu W, et al. The structure of human macrophage inflammatory protein-3alpha/CCL20. Linking antimicrobial and CC chemokine receptor-6-binding activities with human beta-defensins. J Biol Chem. 2002;277:37647–37654
  13. Niyonsaba F, Ogawa H, Nagaoka I. Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils. Immunology. 2004;111:273–281
  14. Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science. 2002;298:1025–1029
  15. Niyonsaba F, Iwabuchi K, Matsuda H, Ogawa H, Nagaoka I. Epithelial cell-derived human beta-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway. Int Immunol. 2002;14:421–426
  16. Scott MG, Vreugdenhil AC, Buurman WA, Hancock RE, Gold MR. Cutting edge: cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein. J Immunol. 2000;164:549–553
  17. Palaniyar N, Nadesalingam J, Reid KB. Pulmonary innate immune proteins and receptors that interact with gram-positive bacterial ligands. Immunobiology. 2002;205:575–594
  18. Steinstraesser L, Tippler B, Mertens J, Lamme E, Homann HH, Lehnhardt M, et al. Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides. Retrovirology. 2005;2:2–13
  19. Yang D, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med. 2000;192:1069–1074
  20. Schutte BC, Mitros JP, Bartlett JA, Walters JD, Jia HP, Welsh MJ, et al. Discovery of five conserved beta-defensin gene clusters using a computational search strategy. Proc Natl Acad Sci U S A. 2002;99:2129–2133
  21. Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394–397
  22. Zarember KA, Godowski PJ. Tissue expression of human toll-like receptors and differential regulation of toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol. 2002;168:554–561
  23. O'Neill LAJ. TLRs: Professor Mechnikov, sit on your hat. Trends Immunol. 2004;25:687–693
  24. Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420:885–891
  25. Kurt-Jones EA, Belko J, Yu C, Newburger PE, Wang J, Chan M, et al. The role of toll-like receptors in herpes simplex infection in neonates. J Infect Dis. 2005;191:746–748
  26. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 2001;410:1099–1103
  27. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A. 2001;98:9237–9242
  28. Kulka M, Alexopoulou L, Flavell RA, Metcalfe DD. Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. J Allergy Clin Immunol. 2004;114:174–182
  29. Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun. 2000;68:6398–6401
  30. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med. 2002;162:1028–1032
  31. Kishore SP, Bungum MK, Platt JL, Brunn GJ. Selective suppression of Toll-like receptor 4 activation by chemokine receptor 4. FEBS Lett. 2005;579:699–704
  32. Borish LC, Steinke JW. Cytokines and chemokines. J Allergy Clin Immunol. 2003;111:5460–5475
  33. Rubinstein M, Dinarello CA, Oppenheim JJ, Hertzog P. Recent advances in cytokines, cytokine receptors and signal transduction. Cytokine Growth Factor Rev. 1998;9:175–181
  34. Oppenheim JJ, Feldman M. In:  Oppenheim JJ,  Feldman M,  Durum SK,  Hirano T,  Vilcek J,  Nicola NA editor. Cytokine reference. San Diego: Academic Press; 2001;p. 3–20
  35. Beutler B, Cerami A. The biology of cachectin/TNFα—primary mediator of the host response. Annu Rev Immunol. 1989;7:625–655
  36. Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA. 1994;271:1836–1843
  37. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. JAMA. 1995;273:934–941
  38. Vanichkin A, Patya M, Gazit A, Levitzki A, Novogrodsky A. Late administration of a lipophilic tyrosine kinase inhibitor prevents lipopolysaccharide and Escherichia coli-induced lethal toxicity. J Infect Dis. 1996;173:927–933
  39. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248–251
  40. Rice TW, Bernard GR. Therapeutic intervention and targets for sepsis. Annu Rev Med. 2005;56:225–248
  41. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 2000;18:217–242
  42. Baggiolini M. Chemokines in pathology and medicine. J Intern Med. 2001;250:91–104
  43. IUIS/WHO Subcommittee on Chemokine Nomenclature . Chemokine/chemokine receptor nomenclature. Cytokine. 2003;21:48–49
  44. Kim CH. Chemokine-chemokine receptor network in immune cell trafficking. Curr Drug Targets Immune Endocr Metabol Disord. 2004;4:343–361
  45. Glass WG, Rosenberg HF, Murphy PM. Chemokine regulation of inflammation during acute viral infection. Curr Opin Allergy Clin Immunol. 2003;3:467–473
  46. Bisset LR, Schmid-Grendelmeier P. Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective. Curr Opin Pulm Med. 2005;11:35–42
  47. McQuibban GA, Butler GS, Gong JH, Bendall L, Power C, Clark-Lewis I, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem. 2001;276:43503–43508
  48. Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, Hoogewerf AJ, et al. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry. 1999;38:12959–12968
  49. Comerford I, Nibbs RJ. Post-translational control of chemokines: a role for decoy receptors?. Immunol Lett. 2005;96:163–174
  50. Rosenkilde MM. Virus-encoded chemokine receptors—putative novel antiviral drug targets. Neuropharmacology. 2005;48:1–13
  51. Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H, et al. Activation of NK cell cytotoxicity. Mol Immunol. 2005;42:501–510
  52. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol. 2001;1:41–49
  53. Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science. 2004;306:1517–1519
  54. Regunathan J, Chen Y, Wang D, Malarkannan S. NKG2D receptor-mediated NK cell function is regulated by inhibitory Ly49 receptors. Blood. 2005;105:233–240
  55. Sato K, Hida S, Takayanagi H, Yokochi T, Kayagaki N, Takeda K, et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol. 2001;31:3138–3146
  56. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2002;2:735–747
  57. Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol. 2005;5:112–124
  58. Joiner KA, Brown EJ, Frank MM. Complement and bacteria: chemistry and biology in host defense. Annu Rev Immunol. 1984;2:461–491
  59. Berger M, Frank MM. The serum complement system. In:  Stiehm ER,  Ochs HD,  Winkelstein JA editor. Immunologic disorders in infants and children. 5th ed.. Philadelphia: Elsevier Saunders; 2004;p. 157–187
  60. Peterson SV, Thiel S, Jensenius JC. The mannan-binding lectin pathway of complement activation: biology and disease association. Mol Immunol. 2001;38:133–149
  61. Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344:1058–1066
  62. Joiner KA. Complement evasion by bacteria and parasites. Ann Rev Microbiol. 1988;42:201–230
  63. Hostetter MK. Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production. J Infect Dis. 1986;153:682–693
  64. Hugli TE. Structure and function of the anaphylatoxins. Springer Semin Immunopathol. 1984;7:193–220
  65. Bhakdi S, Tranum-Jensen J. Complement lysis: a hole is a hole. Immunol Today. 1991;12:318–320
  66. Cooper NR, Nemerow GR. Complement-dependent mechanisms of virus neutralization. In:  Ross GD editors. Immunobiology of the complement system. Orlando (FL): Academic Press; 1986;p. 139–162
  67. Erdei A, Fust G, Gergely J. The role of C3 in the immune response. Immunol Today. 1991;12:332–337
  68. Ochs HD, Nonoyama S, Zhu Q, Farrington M, Wedgwood RJ. Regulation of antibody responses: the role of complement and adhesion molecules. Clin Immunol Immunopathol. 1993;67(suppl):S33–S40
  69. Bottger EC, Bitter-Suermann D. Complement and the regulation of humoral immune responses. Immunol Today. 1987;8:261–264
  70. Metchnikoff E. Immunity in the infectious diseases. 1st ed.. New York: Macmillan Press; 1905;
  71. Bainton DF. Developmental biology of neutrophils and eosinophils. In:  Gallin JI,  Goldstein IM,  Snyderman R editor. Inflammation: basic principles and clinical correlates. 2nd ed.. New York: Raven Press; 1992;p. 303–324
  72. Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood. 1997;90:489–519
  73. Walker RI, Willemze R. Neutrophil kinetics and the regulation of granulopoiesis. Rev Infect Dis. 1980;2:282–292
  74. Anderson DC, Schmalsteig F, Finegold MJ, Hughes BJ, Rothlein R, Miller LJ, et al. The severe and moderate phenotypes of heritable Mac-1, LFA-1, p150, 95 deficiency: Their quantitative definition and relation to leukocyte dysfunction and clinical features. J Infect Dis. 1985;152:668–689
  75. Butcher EC. Leukocyte-endothelial cell recognition: Three (or more) steps to specificity and diversity. Cell. 1991;67:1033–1036
  76. Ley K. The role of selectins in inflammation and disease. Trends Mol Med. 2003;9:263–268
  77. Ley K. Integration of inflammatory signals by rolling neutrophils. Immunol Rev. 2002;186:8–18
  78. Smith CW, Marlin SD, Rothlein R, Toman C, Anderson DC. Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro. J Clin Invest. 1989;83:2008–2017
  79. Berger M, O'Shea J, Cross AS, Folks TM, Chused TM, Brown EJ, et al. Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J Clin Invest. 1984;74:1566–1571
  80. Seo SM, McIntire LV, Smith CW. Effects of IL-8, Gro-alpha, and LTB4 on the adhesive kinetics of LFA-1 and Mac-1 on human neutrophils. Am J Physiol Cell Physiol. 2001;281:C1568–C1578
  81. Gerard C, Gerard N. C5a anaphylatoxin and its seven transmembrane-segment receptor. Annu Rev Immunol. 1994;12:775–808
  82. Anderson DC, Hughes BJ, Smith CW. Abnormal mobility of neonatal polymorphonuclear leukocytes. Relationship to impaired redistribution of surface adhesion sites by chemotactic factor or colchicine. J Clin Invest. 1981;68:863–874
  83. Stossel TP. The mechanical responses of white blood cells. In:  Gallin JI,  Goldstein IM,  Snyderman R editor. Basic principles and clinical correlates. New York: Raven Press; 1992;p. 459–475
  84. Unkeless JC, Shen Z, Lin CW, DeBeus E. Function of human Fc gamma RIIA and Fc gamma RIIIB. Semin Immunol. 1995;7:37–44
  85. van der Pol WL, van de Winkel JGJ. IgG receptor polymorphisms: risk factors for disease. Immunogenetics. 1998;48:222–232
  86. Hostoffer RW, Krukovets I, Berger M. Enhancement by tumor necrosis factor-α of Fcα receptor expression and IgA-mediated superoxide generation and killing of Pseudomonas aeruginosa by polymorphonuclear leukocytes. J Infect Dis. 1994;170:82–87
  87. Stossel TP. Phagocytosis. Prog Clin Biol Res. 1977;13:87–102
  88. Clark RA, Leidal KG, Pearson DW, Nauseef WM. NADPH oxidase of human neutrophils. Subcellular localization and characterization of an arachidonate activatable superoxide-generating system. J Biol Chem. 1987;262:4065–4074
  89. Borregaard N, Heiple JM, Simons ER, Clark RA. Subcellular localization of the b cytochrome component of the human neutrophil microbicidal oxidase: translocation during activation. J Cell Biol. 1983;97:52–61
  90. Root RK, Cohen MS. The microbicidal mechanisms of human neutrophils and eosinophils. Rev Infect Dis. 1981;3:565–598
  91. Tosi MF. Immunologic and phagocytic responses to infection. In:  Feigin RD,  Cherry JD,  Demmler GJ,  Kaplan S editor. Textbook of pediatric infectious diseases. 5th ed.. New York: WB Saunders; 2004;p. 20–62
  92. Spitznagel JK, Dalldorf FG, Leffell MS, Folds JD, Welsh IR, Cooney MH, et al. Character of azurophil and specific granules purified from human polymorphonuclear leukocytes. Lab Invest. 1974;30:774–785
  93. Weiss J, Victor M, Elsbach P. Role of charge and hydrophobic interactions in the action of the bactericidal/permeability-increasing protein of neutrophils on gram-negative bacteria. J Clin Invest. 1983;71:540–549
  94. Levy O, Weiss J, Zarember K, Ooi CE, Elsbach P. Antibacterial 15-kDa protein isoforms (p15s) are members of a novel family of leukocyte proteins. J Biol Chem. 1993;268:6058–6063

 Series editor: Harold S. Nelson, MD

 Disclosure of potential conflict of interst: M. F. Tosi—none disclosed.

PII: S0091-6749(05)01364-3

doi: 10.1016/j.jaci.2005.05.036

The Journal of Allergy and Clinical Immunology
Volume 116, Issue 2 , Pages 241-249 , August 2005

Article Tools

* Image Usage & Resolution